Supply Chain Disruption and Going Concern Doubt Flagged by Nuo Therapeutics
AURX is trading near its 52-week low of $0.77 (0.0% above the low).
Summary
Nuo Therapeutics' Q2 2026 report discloses a supply chain disruption for a critical reagent and reiterates going concern doubt with minimal cash reserves.
Key Events · Earnings and Guidance · AURX
-
Supply Chain Disruption
In late June 2026, Pfizer notified Nuo that bovine thrombin (TJMI) would be unavailable, with recovery expected in early 2027. Aurix and Private Label products entered a temporary out-of-stock in early August 2026.
-
Going Concern Doubt
Cash stood at $0.4 million as of June 30, 2026. Management states substantial doubt about the company's ability to continue as a going concern for the next 12 months.
-
Material Weaknesses
Disclosure controls and procedures remain ineffective due to previously identified material weaknesses in internal control over financial reporting.
-
Revenue Growth
Q2 2026 revenue was $1.77 million, up 153% year-over-year, driven by Aurix product sales and Smith+Nephew private label distribution.
Analysis · AURX · Industrial Applications And Services
A critical supply chain interruption for bovine thrombin—a key reagent sourced solely from Pfizer—is disclosed in the 10-Q, causing a temporary out-of-stock in early August 2026. While an alternative short-term supply has been secured, long-term resolution remains uncertain. Substantial doubt about the company's ability to continue as a going concern is also reiterated, with only $0.4 million in cash as of June 30, 2026. These factors pose significant risk to the company's ability to sustain operations and meet revenue targets.
At the time of this filing, AURX was trading at $0.77 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $37.3M. The 52-week trading range was $0.77 to $3.23. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.